The drugs could fetch more than $2 billion (£1.6 billion), Bloomberg reported.
Pfizer is working with financial adviser JPMorgan Chase & Co for the potential portfolio sale and the process is at a preliminary stage, Bloomberg said.
Pfizer could not be immediately reached for comment.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Savio D'Souza)